[go: up one dir, main page]

PA8616201A1 - Composiciones farmaceuticas de liberacion sostenida - Google Patents

Composiciones farmaceuticas de liberacion sostenida

Info

Publication number
PA8616201A1
PA8616201A1 PA20048616201A PA8616201A PA8616201A1 PA 8616201 A1 PA8616201 A1 PA 8616201A1 PA 20048616201 A PA20048616201 A PA 20048616201A PA 8616201 A PA8616201 A PA 8616201A PA 8616201 A1 PA8616201 A1 PA 8616201A1
Authority
PA
Panama
Prior art keywords
pharmaceutical compositions
sustained liberation
liberation
sustained
aplindore
Prior art date
Application number
PA20048616201A
Other languages
English (en)
Inventor
Eric J Benjamin
Wendy A Dublin
Yanning Lin
Kai Zhuang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34572826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8616201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8616201A1 publication Critical patent/PA8616201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROVEE FORMULACIONES DE DOSIS DE LIBERACION CONTROLADA DE COMPUESTO QUE TIENEN LA FORMULA: O LAS SALES FARMACEUTICAS ACEPTABLES DE LO MISMO, Y EN PARTICULAR, APLINDORE. LAS FORMAS DE DOSIS SON UTILES, INTER ALIA, PARA REDUCIR LOS EFECTOS COLATERALES DEBIDO A LA ADMINISTRACION DE TALES COMPUESTOS.
PA20048616201A 2003-10-29 2004-10-28 Composiciones farmaceuticas de liberacion sostenida PA8616201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51531503P 2003-10-29 2003-10-29

Publications (1)

Publication Number Publication Date
PA8616201A1 true PA8616201A1 (es) 2005-05-24

Family

ID=34572826

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048616201A PA8616201A1 (es) 2003-10-29 2004-10-28 Composiciones farmaceuticas de liberacion sostenida

Country Status (22)

Country Link
US (5) US20050095292A1 (es)
EP (1) EP1675583B1 (es)
JP (1) JP5547865B2 (es)
KR (1) KR101409724B1 (es)
CN (2) CN1874767A (es)
AR (1) AR046222A1 (es)
AU (1) AU2004286855B2 (es)
BR (1) BRPI0415953B8 (es)
CA (1) CA2543045C (es)
ES (1) ES2405404T3 (es)
GT (1) GT200400218A (es)
HK (1) HK1089394A1 (es)
IL (1) IL174958A (es)
MX (1) MXPA06004752A (es)
NO (1) NO20062004L (es)
PA (1) PA8616201A1 (es)
PE (1) PE20050484A1 (es)
RU (1) RU2376988C2 (es)
SG (1) SG147450A1 (es)
TW (1) TW200517106A (es)
WO (1) WO2005044262A1 (es)
ZA (1) ZA200603409B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101409724B1 (ko) 2003-10-29 2014-06-19 와이어쓰 엘엘씨 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물
US8858993B2 (en) * 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
MX2008002512A (es) * 2005-08-26 2008-04-03 Bpsi Holdings Inc Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
CN102264363A (zh) * 2008-12-22 2011-11-30 诺瓦提斯公司 S1p受体激动剂的给药方案
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
EP2744496A4 (en) 2011-08-16 2015-04-08 Baker Idi Heart And Diabetes Inst Holdings Ltd FORMULATIONS WITH TAXED RELEASE
WO2014031892A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CA2971071A1 (en) 2014-12-22 2016-06-30 Cardiora Pty Ltd Use of milrinone and derivatives thereof in the treatment of heart failure with preserved ejection fraction (hfpef)
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
JP2020525436A (ja) 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
JP6983139B2 (ja) * 2017-11-27 2021-12-17 信越化学工業株式会社 固形製剤用組成物並びに固形製剤及びその製造方法
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
EP3737676B1 (en) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
IL295341B2 (en) * 2018-09-28 2025-01-01 Karuna Therapeutics Inc Compositions and methods for treating diseases improved by activating muscarinic receptors
TWI841545B (zh) * 2018-12-12 2024-05-11 日商田邊三菱製藥股份有限公司 耐胃性控制釋放經口劑型
CN115710224A (zh) * 2020-06-28 2023-02-24 海创药业股份有限公司 一种喹啉类化合物晶型及其制备方法
CN116549406B (zh) * 2023-05-23 2023-12-19 北京丰科睿泰医药科技有限公司 一种盐酸曲唑酮缓释片剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
AU639536B2 (en) 1990-03-15 1993-07-29 Pharmacia & Upjohn Company Therapeutically useful heterocyclic indole compounds
JP2600978B2 (ja) * 1990-05-25 1997-04-16 日産自動車株式会社 サスペンションのアッパリンク支持部構造
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5168387A (en) * 1990-12-11 1992-12-01 Central Glass Company, Limited Variable light transmittance device
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5166367A (en) 1991-06-21 1992-11-24 American Home Products Corporation Antipsychotic benzodioxan derivatives
US5126366A (en) 1991-06-21 1992-06-30 American Home Products Corporation Aminophenoxyalkyl derivatives of benzodioxan
US5189171A (en) 1991-06-21 1993-02-23 American Home Products Corporation Antipsychotic benzodioxan derivatives
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5245051A (en) * 1992-09-03 1993-09-14 American Home Products Corporation Antipsychotic chroman derivatives of benzodioxanmethylamine
DK0605033T3 (da) 1992-12-21 2000-02-07 Duphar Int Res Enzymatisk fremgangsmåde til stereoselektiv fremstilling af en heterobicyklisk alkoholenantiomer
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US6126970A (en) * 1995-12-01 2000-10-03 Janssen Pharmaceutica N.V. Cisapride sustained release
JPH09315969A (ja) * 1996-05-24 1997-12-09 Taiyo Yakuhin Kogyo Kk イブジラスト含有徐放性医薬品組成物及びその製造方法
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
DE60042215D1 (de) * 1999-07-13 2009-06-25 Alpha Res Group Llc Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
ES2236017T3 (es) * 1999-12-03 2005-07-16 Polichem S.A. Procedimientos para la prepaaraciones farmaceuticas de liberacion sostenida de alcaloides del ergot que tienen biodfisponibilidad mejorada y composiciones de los mismos.
AU784211B2 (en) 1999-12-10 2006-02-23 Wyeth Combinations of (S)-2(benzylamino-methyl)-2,3,8,9,- tetrahydro-7H-1,4-dioxino(2,3)-E indol-8-one and neuroleptics
US6350773B1 (en) * 1999-12-10 2002-02-26 American Home Products Corporation Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
US6524618B1 (en) * 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
EP1663166A2 (en) * 2003-09-02 2006-06-07 Imran Ahmed Sustained release dosage forms of ziprasidone
KR101409724B1 (ko) 2003-10-29 2014-06-19 와이어쓰 엘엘씨 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물
TW200811182A (en) 2006-05-25 2008-03-01 Wyeth Corp Oxindoledioxans, synthesis thereof, and intermediates thereto

Also Published As

Publication number Publication date
US11179369B2 (en) 2021-11-23
AU2004286855B2 (en) 2011-04-21
CA2543045A1 (en) 2005-05-19
CA2543045C (en) 2013-12-17
SG147450A1 (en) 2008-11-28
CN102335116A (zh) 2012-02-01
AU2004286855A1 (en) 2005-05-19
WO2005044262A1 (en) 2005-05-19
KR101409724B1 (ko) 2014-06-19
AR046222A1 (es) 2005-11-30
US20180344695A1 (en) 2018-12-06
US10292966B2 (en) 2019-05-21
NO20062004L (no) 2006-07-07
RU2376988C2 (ru) 2009-12-27
KR20060110281A (ko) 2006-10-24
US10463648B2 (en) 2019-11-05
CN1874767A (zh) 2006-12-06
GT200400218A (es) 2005-06-06
ES2405404T3 (es) 2013-05-31
PE20050484A1 (es) 2005-10-13
JP5547865B2 (ja) 2014-07-16
BRPI0415953A (pt) 2007-01-02
US20230061743A1 (en) 2023-03-02
JP2007509970A (ja) 2007-04-19
TW200517106A (en) 2005-06-01
EP1675583B1 (en) 2013-02-27
IL174958A0 (en) 2008-04-13
BRPI0415953B8 (pt) 2021-05-25
ZA200603409B (en) 2010-10-27
US20200138781A1 (en) 2020-05-07
US20050095292A1 (en) 2005-05-05
EP1675583A1 (en) 2006-07-05
RU2006118321A (ru) 2007-12-10
BRPI0415953B1 (pt) 2018-12-26
HK1089394A1 (en) 2006-12-01
MXPA06004752A (es) 2006-07-05
US20180193311A1 (en) 2018-07-12
IL174958A (en) 2012-08-30

Similar Documents

Publication Publication Date Title
PA8616201A1 (es) Composiciones farmaceuticas de liberacion sostenida
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
CR9662A (es) Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas
SV2004001418A (es) Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248
ECSP066534A (es) Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia
ES2150489T3 (es) 1-amidinofenil-pirrolidonas, -piperidinonas, -azetinonas como inhibidores de la agregacion de plaquetas.
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
SV2003001493A (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
CR8859A (es) Derivados de piridina
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
PA8592201A1 (es) Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
UY30460A1 (es) Compuestos terapéuticos
HN2003000185A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso.
PA8580601A1 (es) Composicion farmaceutica de altas dosis
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina